A dual-axis safety framework enables risk-adapted MR-linac prostate SBRT with cardiac devices

A new framework combines MRI and radiotherapy device risks into six operational classes for prostate SBRT on a 1.5-T MR-linac.

KEY POINTS

  • This special article from NYU Grossman School of Medicine describes a multidisciplinary risk framework for patients with cardiac implantable electronic devices (CIEDs) undergoing prostate SBRT on a 1.5-T Elekta Unity MR-linac. The framework integrates diagnostic MRI safety guidance with radiotherapy-specific device risks, drawing on AAPM TG-203, TG-158, the 2026 ACR Manual on MR Safety, and electrophysiology recommendations. It is implemented prospectively at the institution, but the publication reports no new patient-level device safety outcomes.
  • The framework assesses MRI and radiotherapy risks independently before combining them into six categories. The MRI axis considers complete generator–lead system conditionality, lead configuration, battery reserve, radiofrequency exposure, gradient limits, and safe device programming. The RT axis accounts for neutron production, cumulative generator dose, direct-beam exposure, and pacing dependence. Their intersection produces LOW, LOW/INTERMEDIATE, INTERMEDIATE, INTERMEDIATE/HIGH, HIGH, or HOLD, each linked to specific monitoring and staffing requirements.
  • Radiotherapy risk is primarily determined by device exposure and pacing dependence. Low risk requires a non-neutron-producing beam, cumulative generator dose <2 Gy, and pacing independence. Intermediate risk includes pacing dependence with generator dose <2 Gy or generator doses of 2–5 Gy; pacing-dependent patients receiving 2–5 Gy require further escalation. Neutron-producing treatment, direct device irradiation, or generator dose >5 Gy places patients in the high-risk category, for which CT-guided treatment is the default.
  • MRI-related contraindications can override otherwise favorable radiation characteristics. A fully MR-conditional generator–lead system meeting all manufacturer conditions may qualify as MR-low risk, whereas selected nonconditional systems require an individualized protocol. Abandoned or epicardial leads, recent device revisions, or limited battery reserve require higher-level review. Noninterrogable devices, end-of-life batteries, fractured leads, and unresolved device identification can trigger MR-HOLD, precluding MR-guided treatment until the problem is resolved.
  • The clinical workflow is designed around five-fraction prostate SBRT. Intact-prostate prescriptions were 40 Gy in five fractions, with an optional 45-Gy simultaneous integrated boost to the dominant intraprostatic lesion; salvage schedules delivered 35–40 Gy in five fractions. Online adaptive planning, cine MRI, and intrafraction gating were incorporated. Observed non-cine MRI acquisition time was 4.5–6.5 minutes per fraction, with an additional 8.5–16.3 minutes of cine imaging; exposure limits must follow the specific device's labeling rather than a universal scan-duration cutoff.
  • Each treatment fraction requires coordinated monitoring, interrogation, and emergency preparedness. Eligible patients undergo continuous ECG and pulse-oximetry monitoring, audiovisual communication, device programming and restoration, and risk-class-specific blood pressure monitoring. Every fraction requires an ACLS-certified radiation oncologist, medical physicist, credentialed CIED personnel, and radiation therapists, with electrophysiology coverage determined by risk class. Device restoration and interrogation are verified after treatment, and emergency equipment is stationed outside the MRI treatment zone.
  • The risk matrix is an institutional operational framework rather than a validated safety classification. Existing direct evidence for treatment on a 1.5-T MR-linac remains limited to small heterogeneous case series, while the proposed thresholds and escalation procedures partly rely on extrapolation from diagnostic MRI and conventional radiotherapy. The framework applies specifically to pelvic prostate SBRT with a remote pectoral generator and non-neutron-producing treatment. Its safety, scalability, and predictive performance require prospective multicenter evaluation.

CLINICAL TAKEAWAY

Patients with cardiac implantable electronic devices should not necessarily be excluded categorically from MR-guided prostate SBRT, but treatment requires independent assessment of MRI and radiation risks with coordinated electrophysiology support. This framework provides a structured approach to clearance, monitoring, programming, and emergency response. It is not yet outcome-validated and should not be adopted without the personnel, equipment, and institutional protocols necessary to implement its safeguards.

SOURCE

Practical Radiation Oncology

Browse more research Suggest a correction